Louisiana Department of Health - Office of Public Health
Louisiana Department of Health - Office of Public Health was paid $37.92M by Medicaid between Jan 2018 and Nov 2024, across 50 billing codes. Its largest line is 87591, Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe — 10.0% of everything it billed.
BATON ROUGE, LA 70802
Next to other Clinical Medical Laboratory providers in Louisiana
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 435,820 | $5.56M | |
| 2019 | 381,106 | $5.32M | |
| 2020 | 390,644 | $6.23M | |
| 2021 | 324,037 | $5.62M | |
| 2022 | 354,564 | $4.86M | |
| 2023 | 349,597 | $6.04M | |
| 2024incomplete | 234,175 | $4.29M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 10.0% | 117,727 | 94,288 | $3.79M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 10.0% | 117,587 | 94,214 | $3.78M |
| 82775 | 9.6% | 223,757 | 181,108 | $3.66M | |
| 83789 | 9.1% | 223,065 | 180,697 | $3.46M | |
| 84143 | 9.1% | 190,091 | 153,491 | $3.44M | |
| 83021 | 8.5% | 223,239 | 181,116 | $3.23M | |
| 82261 | 8.2% | 223,565 | 181,113 | $3.12M | |
| 84443 | Thyroid stimulating hormone (TSH) | 7.7% | 226,129 | 181,134 | $2.92M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.9% | 36,433 | 19,561 | $2.60M |
| 83516 | 5.3% | 223,648 | 181,117 | $2.00M | |
| 81479 | Unlisted molecular pathology procedure | 3.9% | 164,806 | 133,639 | $1.49M |
| 84437 | 3.0% | 223,667 | 181,129 | $1.12M |
38 more codes
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 1.8% | 3,801 | $692K |
| 83498 | 1.6% | 38,765 | $623K | |
| 86318 | 1.2% | 47,391 | $454K | |
| 86703 | 1.0% | 47,676 | $387K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 20,366 | $292K |
| 81025 | <1% | 35,436 | $185K | |
| 83020 | <1% | 13,100 | $135K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 4,318 | $117K |
| 86481 | <1% | 1,768 | $74K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,931 | $69K |
| 86780 | <1% | 5,356 | $57K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,158 | $36K |
| 87210 | <1% | 10,532 | $32K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,849 | $31K |
| 86803 | <1% | 2,284 | $24K | |
| 86592 | <1% | 4,053 | $13K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 315 | $12K |
| 87116 | <1% | 1,410 | $9K | |
| 86593 | <1% | 2,312 | $8K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 5,233 | $7K |
| 81002 | <1% | 3,274 | $7K | |
| 84450 | <1% | 2,207 | $6K | |
| 85018 | <1% | 3,003 | $6K | |
| 87206 | <1% | 1,390 | $5K | |
| 84460 | <1% | 1,469 | $4K | |
| 88142 | <1% | 4,504 | $4K | |
| 82565 | <1% | 1,297 | $4K | |
| 84550 | <1% | 1,454 | $3K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 57 | $3K |
| 82247 | <1% | 1,518 | $3K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 87 | $2K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 582 | $2K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,434 | $1K |
| 82948 | <1% | 281 | $678.13 | |
| 86701 | <1% | 143 | $477.36 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 133 | $170.28 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 15 | $117.60 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 1,327 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Louisiana Department of Health - Office of Public Health | New Orleans, LA | $3.67M |
| Louisiana Department of Health - Office of Public Health | Baton Rouge, LA | $2.66M |
| Louisiana Department of Health - Office of Public Health | New Orleans, LA | $2.55M |
| Louisiana Department of Health - Office of Public Health | New Orleans, LA | $1.51M |
| Louisiana Department of Health - Office of Public Health | Baton Rouge, LA | $838K |
| Louisiana Department of Health - Office of Public Health | New Orleans, LA | $594K |
| Office of Public Health -Genetics Diseases Program | New Orleans, LA | $44K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.